Promising Research Finds Natural Compounds May Aid in Alzheimer's Disease Management
May 28, 2024
Recent studies have uncovered promising benefits of natural compounds found in pomegranates, strawberries, and walnuts that could aid in managing Alzheimer's disease. Researchers have identified a substance known as urolithin A, which has been shown to restore the brain's ability to detect and eliminate damaged cells in mouse models of Alzheimer's.
This discovery builds on earlier findings by the same team, which revealed that nicotinamide riboside (NR), a form of vitamin B3, enhances the removal of damaged mitochondria from the brain. Disruptions in this "clean-up" process can lead to the accumulation of cellular debris, setting the stage for neurodegenerative diseases such as Alzheimer's and Parkinson's.
Vilhelm Bohr, a biochemist at the University of Copenhagen, explains, "Mitophagy, or the removal of weak mitochondria, is often impaired in neurodegenerative diseases, leading to mitochondrial dysfunction. Stimulating this process can yield significantly positive outcomes by clearing out the brain trash that contributes to amyloid plaques and neurofibrillary tangles characteristic of Alzheimer's."
The research indicates that long-term treatment with urolithin A in mice resulted in improved cognitive functions such as learning, memory, and olfactory senses. The substance appears to regulate the overactive cathepsin Z protein in Alzheimer's brains, which is involved in inflammation. By reducing the production of this protein, urolithin A helps restore certain cellular processes essential for breaking down biological waste.
Moreover, urolithin A also seems to modulate immune responses and other physiological pathways associated with Alzheimer's, suggesting its potential to slow the progression of the disease. Bohr notes, "Using a natural substance like urolithin A reduces the risk of side effects, which is a significant advantage. While we understand the impacts of NAD supplementation well, our knowledge of urolithin A is still developing. However, its effectiveness in clinical trials for muscular diseases encourages us to explore its potential for Alzheimer's."
Although the results are based on animal studies and thus cannot be directly translated to humans, they provide a strong foundation for future clinical trials. Bohr remains optimistic, stating, "We are still determining the effective dosage, but it is clear that the amount needed is more than just consuming a pomegranate a day. Fortunately, urolithin A is already available in pill form, and we are actively working to establish the right dosage for therapeutic use."
As researchers continue to investigate, the hope is that these natural compounds could one day contribute significantly to the management of Alzheimer's disease, potentially slowing its progression and improving quality of life for those affected.
